To provide an overview of the current state of the evidence and highlight recent advances in the evaluation and diagnosis of clinically significant prostate cancer, focusing on biomarkers, risk calculators and multiparametric MRI (mpMRI).
INTRODUCTION
Population-based screening for prostate cancer with prostate-specific antigen (PSA) is controversial because of the imbalance between the magnitude of benefits, in terms of reduction in the risk of metastasis [1] and death from the disease [2
&&
,3], relative to the magnitude of harm in terms of overdiagnosis [4, 5 && ] and risk of overtreatment with sideeffects from surgery or radiation and deterioration of quality of life [6] . For these reasons, there is a call for a better screening test that can detect aggressive tumors that are destined to become lethal during the man's lifetime, while avoiding the detection of low-grade tumors. There is an urgent need for biomarkers, or multivariable approaches, that can improve the specificity of PSA [7] , while maintaining its sensitivity, to achieve a better balance between benefits and harms. This review focuses on recent advances in biomarker/risk-stratification approaches to the detection of clinically significant prostate cancer, particularly evaluating the effects on cancers detected versus cancers missed, and number of biopsies avoided.
DETERMINING THE NEED FOR SCREENING
Before discussing which biomarkers and approaches for risk-stratified screening are available to improve the detection of clinically significant prostate cancer, it deserves mentioning that 'smarter' screening and optimization of the balance between benefits and harms can also be achieved through 'upstream' approaches, that is, by carefully selecting only those men for screening who are believed to be at highest risk of aggressive or life-threatening prostate cancer. Doing so implies enriching the cohort of men who are more likely to be subjected to biopsy to those at highest risk of high-grade disease. Guideline groups differ regarding what defines 'high risk' and includes risk factors for prostate cancer outcomes and fitness for curative therapy, such as: age, general health/life expectancy, race/ethnicity, family history, and the baseline PSA-level in midlife [8,9,10 & ,11] . Many guideline groups recommend PSA screening, after shared decision-making, to start when a man is in his 40s to 50s and end in the early-mid 70s [8] A recent 2016 microsimulation modeling study showed that the balance between benefits and harms of current screening and treatment practices could be improved four-fold if a few simple guidelines were followed: limited screening in older men, additional biomarkers added to PSA before proceeding to biopsy, recommending initial active surveillance to most men with low-risk prostate cancer, and curative treatment delivered by high-volume physicians or centers [12 && ]. Interestingly, stopping screening at age 70 and increasing the utilization of active surveillance had substantial effects on quality-adjusted life years, compared with moderate effects of the addition of novel biomarkers before biopsy. This implies that the downstream negative consequences of PSA is perhaps not so much the poor test characteristics, but rather lack of adherence to guidelines emphasizing 'smarter' approaches, for example, overuse of the PSA test when not indicated and suboptimal management of screen-detected tumors.
DETERMINING THE NEED FOR PROSTATE BIOPSY
Once a man has been screened with PSA, several 'reflex tests' are available to help the man and his physician determine the need for prostate biopsy. Avoiding unnecessary biopsy is critical to avoiding exposing men to an uncomfortable and risky invasive procedure, and to avoid labeling men with a cancer diagnosis with ensuing psychological stress. Because the purpose of this review is to highlight studies from the past year, focus will be on the recent National Comprehensive Cancer Network (NCCN) version 2.2016 guideline.
Initial biopsy setting: repeating the prostate-specific antigen and work-up for benign disease
In the initial biopsy setting, following an elevated PSA level more than 3 ng/ml, the NCCN first recommends to repeat the PSA after a few weeks to confirm an elevated value. This is because PSA tends to fluctuate from one measurement to another [13] [14] [15] , as first shown by Eastham et al. [13] in a landmark study from a dietary study to prevent colon polyps in which men had annual serial blood draws over a 5-year period; the probability that the PSA-level would return to normal, and remain normal, was high, more than 40 and 65%, respectively. The commonality of PSA fluctuations was recently confirmed in a 2016 study by Nordström et al. from a screening study in Stockholm (STHLM), Sweden, furthering the evidence that omitting prostate biopsy for men with PSA 3-10 ng/ml which subsequently returned to below 3 ng/ml 8 weeks later could save 17% of biopsies while missing only 5% of Gleason score 7 or higher [14] . Another recent 2016 study from Canada similarly showed that among men with referral PSA levels between 4-10 ng/ml, repeated PSA tests results in the same laboratory fell below 4 ng/ml in 25% of men [15] . In addition to repeating the PSA, NCCN 2016 also suggests following up an elevated PSA value with clinical work-up for benign prostatic disease including DRE and estimation of prostate volume [10 & ].
KEY POINTS
Early detection of prostate cancer has benefits (reduction in risk of metastasis and prostate cancer death), but certainly also harms (false positives, overdiagnosis and related overtreatment).
There are numerous options to improve early detection as compared to a purely PSA-based approach, including reflex biomarkers and risk calculators. All have their strengths and drawbacks.
Cost-effectiveness analyses are crucial and needed.
MRI in the prediagnostic setting holds promise but is not yet ready for 'prime time.'
Initial biopsy setting: blood biomarkers free-to-total prostate-specific antigen, Prostate Health Index, and 4-kallikrein score
Next, the 2016 NCCN guideline recommends any of the following reflex tests (blood) to follow an elevated PSA more than 3 ng/ml: free-to-total PSA (%fPSA), 4-kallikrein score (4KScore), or Prostate Health Index (PHI) [10 & ].
Free prostate-specific antigen Free PSA is a component of both PHI and 4Kscore and removing free PSA from the 4Kscore reduced the area under the curve (AUC) from 0.82 to 0.70 in a recent US validation study [16] . A lower %fPSA suggests greater risk of prostate cancer (any grade). The test is approved by the US Food and Drug Administration (FDA) for men with normal DRE and total PSA between 4 and 10 ng/ml. In a study of men with PSA between 4 and 10 ng/ml and normal DRE, prostate cancer (any grade) was found in 56% of men with a %fPSA less than 10%, in contrast to 8% cancer among men with %fPSA more than 25% [17] . NCCN 2016 thus recommends less than 10% as an informative cut-off in men who have never undergone biopsy (or after negative biopsy) [10 & ]. In addition, recently published data from the San Antonio Biomarkers of Risk of prostate cancer Study comprising 6982 serial %fPSA and PSA measurements over 10 years showed that %fPSA as a reflex test to PSA could save 2/3 of unnecessary biopsies [18] . Using a cut-off of less than 25% free PSA provided the first cancer suspicion (before total PSA) 71% of the time (34% if using <15% as a cutoff). Like total PSA levels, fluctuations of %fPSA are common, particularly among men never diagnosed with prostate cancer. Some, therefore, suggest repeating a %fPSA for men with PSA less than 4 ng/ml so that a spurious value does not prompt unnecessary biopsy [18] .
Prostate Health Index
The PHI is a test approved by the FDA in 2012 to be used in men over the age of 50, with a PSA in the range 2-10 ng/ml and negative DRE. It is based on a mathematical formula of the measured biomarkers [PHI ¼ ([À2]proPSA/free PSA) Â Htotal PSA]. Similar to %fPSA, it is intended as a secondary aid to PSA to distinguish any prostate cancer from benign prostatic condition, as cancer releases more proPSA and freePSA than benign prostatic hyperplasia [19,20 & ]. NCCN considers a PHI more than 35 as potentially informative in men who have never undergone biopsy (or after negative biopsy) [10 & ]. In a large, prospective, multicenter study in the United States of 892 men with a PSA 2-10 ng/ml, PHI improved the detection of any prostate cancer and Gleason score at least 4 þ 3 ¼ 7 compared with free PSA and total PSA (AUC 0.78-0.82). A PHI cut-off of at least 25 for biopsy could avoid 36-41% of unnecessary biopsies and 17-24% of overdiagnoses, while missing 5% of tumors with Gleason score 7 or higher [21] .
4-kallikrein score
The 4Kscore is a combination of free, total, intact PSA and Human Kallikrein 2 (hK2) with age, DRE, and prior biopsy information. The test predicts risk of aggressive prostate cancer (high grade) [22] and it has recently been shown to be associated with longterm risk of metastasis among unscreened men with elevated PSA at least 3 ng/ml at age 60; among men with a 'low' 4Kscore below 7.5% (38% of men) the 10-year risk of metastasis was 0.2% [ ]. In the validation study, a large, prospective, multicenter study of 1012 men in the US scheduled for biopsy, regardless of PSA level, the test decreased unnecessary biopsies by 30-58%, without delaying an undue number of high-grade cancers (1.3-4.7%) [16] . In a recent 'impact study' conducted in routine clinical care in 611 patients with abnormal PSA and/ or DRE, 65% of men did not have a biopsy after the 4Kscore test result was received [25] . In a recent 2016 study conducted within a multiethnic cohort in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial screening trial, the 4K-panel improved the prediction of high-grade prostate cancer over total PSA (AUC 0.80 vs. 0.67). Using a cut-off of 6% risk of high-grade disease to determine biopsy kept the detection of high-grade disease by 88% and reduced unnecessary biopsies by 42% [26] .
Next to serum based markers also urine based biomarkers are being investigated in the initial biopsy setting. Two novel urine markers are SelectMDx and Michigan Prostate Score (MiPS).
SelectMDx
SelectMDx as developed by MDxHealth (Irvine, CA, USA) is performed on post-DRE, first-void urine and measures the mRNA levels of the HOXC6 and DLX1 biomarkers, using KLK3 expression as internal reference. The first evaluation resulted in AUC of 0.86 for significant prostate cancer on multivariable analysis, and a 42% reduction in biopsies with 2% high-grade cancers missed. However, a clinical base model without SelectMDx (age, PSA, PSA density, family history, DRE, and prior biopsy) had a high AUC by itself (0.87), mainly driven by PSA density [27] . The test is not FDA approved but performed in a CLIA-accredited laboratory.
Michigan Prostate Score
The MiPS, as developed by the University of Michigan MLabs (Ann Arbor, Michigan, USA), is a multiplex urine analysis of Prostate Cancer Antigen 3 (PCA3) and TMPRSS2:ERG combined with serum PSA, designed to detect high-grade prostate cancer (Gleason score 7 or higher) on biopsy after initial PSA testing. The test is not FDA approved (as of 2016) [28 && ]. A first evaluation, using a 30% risk threshold for biopsy, showed a halving of the number of biopsies (16% of biopsies avoided with the Prostate Cancer Prevention Trial (PCPT) risk calculator vs. 35% with PCPT-risk calculator and MiPS) whereas missing, or delaying, 1% of high-grade cancers [29] .
Initial biopsy setting: risk calculators

Risk calculators
Nomograms, or risk calculators, have the advantage of incorporating easy to retrieve clinical variables such as age, family history, DRE, PSA density, with or without biomarkers [30] . In a recent meta-analysis of six nomograms predicting risk of any prostate cancer on biopsy (Prostaclass, Finne, Karakiewicz, PCPT, Chun, ERSPC-risk calculator3), most risk calculators performed better than PSA alone in terms of discrimination (AUC) [31 & ]. However, guidelines leave the decision which risk calculator to use to the physician's discretion. It is important to utilize a risk calculator in the clinical setting and the population in which it was developed. As an example of the clinical utility of using a risk calculator, an ERSPCrisk calculator combining PSA with DRE, Transrectal Ultrasound (TRUS) and prostate volume with biopsy at a cut-off of 12.5% risk, could avoid 33% of biopsies while missing no lethal prostate cancer cases compared with PSA alone and biopsy at a cut-off of 3 ng/ ml [32] . Biomarkers such as %fPSA, PHI, and PCA3 can be integrated into risk calculators together with clinical information, for example, the ERSPC-risk calculator, the PCPT-risk calculator and the Sunnybrook risk calculator, with improvements in the AUC when adding these biomarkers to clinical information such as age, family history, DRE, and prior biopsy [19,20 & ,33,34] . As an example, adding PHI to the PCPT-risk calculator or ERSPC-risk calculator improves the predictive accuracy of aggressive disease [35] .
Repeat biopsy setting: biomarkers in blood, urine, and biopsy tissue Some men will have negative prostate biopsy and persistently elevated PSA levels more than 3 ng/ml. In this repeat biopsy setting, the most recent NCCN guideline version 2.2016 recommends utilization of %fPSA (blood), 4Kscore (blood), PHI (blood), PCA3 (urine), and ConfirmMDx (prostate biopsy tissue) [10 & ].
PCA3
PCA3 is a noncoding mRNA that is overexpressed in prostate cancer and can be measured in urine after DRE. Numerous studies show that PCA3 can better predict any prostate cancer on repeat biopsy compared with PSA and clinical models [36] [37] [38] . However, the reason the test is FDA approved only for men at least 50 years with previous negative biopsy and other indications for repeat biopsy, is because there is conflicting data regarding the relationship between PCA3 and prostate cancer aggressiveness [20 & ,39,40] and a risk of 13% high-grade prostate cancer missed among men with low PCA3 scores less than 20 in the initial setting in the US validation study (compared with 3% in the repeat setting) [41] . An appropriate cut-off level with acceptable performance characteristics has been difficult to define for PCA3 and NCCN recommends a PCA3 score more than 35 as informative after a negative biopsy [10 & ].
ConfirmMDx
ConfirmMDx as developed by MDxHealth (Irvine, CA, USA) is a tissue-based epigenetic test that can help decrease unnecessary repeat biopsy. The negative predictive value was 88% in a study of 350 men with negative biopsy and repeat biopsy within 2 years [42] . The test builds on a ''field effect'' phenomenon, that is, benign prostatic tissue adjacent to a cancer focus showing distinct epigenetic alterations [42] [43] [44] . Because of limited available data, there is no recommendation regarding the routine clinical application. The test is not FDA approved but performed in a CLIA-accredited laboratory.
Multiplex test: stockholm-3 46] . As compared with PSA only with a cut-off of 3 ng/ml to determine biopsy, use of the STHLM3 test in all men with PSA more than 1 ng/ml decreased overdiagnosis by 17% and reduced the number of unnecessary biopsies by 32% [45 && ]. The number of high-grade cancers caught and missed by utilization of the STHLM3 test, as compared with PSA alone, could not be assessed, because of the paired screen-positive study design of the trial in which not all men were biopsied to verify presence or absence of the diagnosis [47] . Moreover, because some components of the STHLM3 test were added before the plasma protein biomarkers in the statistical evaluation of the test, that is, the genetic information and family history, it is difficult to compare the performance characteristics of STHLM3 test with other multiplex tests such as 4Kscore and the ERSPC or PCPT-risk calculators [47] .
Multiplex test: 'liquid biopsy'
A recent 2016 study on 319 patients with indication for prostate biopsy measured a panel of gene expression levels ('liquid biopsy') in plasma and urine (UAP1, PDLIM5, IMPDH2, HSPD1, PCA3, PSA, TMPRSS2, ERG, GAPDH, B2M, AR, and PTEN), along with serum PSA and age, to screen for best biomarker combinations to predict high-grade prostate cancer in a multivariable logistic model [48] . The AUC for the 13 variables was 0.85, and 0.80 if only eight were included. Whether this model improves predictions over clinical base models and reduces the number of biopsies is yet unknown.
MRI in the prediagnostic setting mpMRI MRI has long played a role in staging and surgical planning. However, because prostate cancer is often multifocal, use of MRI alone in the prediagnostic setting before biopsy has been a less attractive strategy, as compared with, for example, mammography or MRI in breast cancer screening. With the technological advancements in recent years and increasing experience among technicians, radiologists, urologists, and pathologists, mpMRI has evolved as an increasingly appealing tool in the diagnostic arsenal, mainly to guide biopsies toward suspicious lesions, to maximize the detection of high-risk disease (Gleason at least 4 þ 3) and limit the detection of low-risk disease (Gleason 6 or lower volume 3 þ 4) [10 & ]. Several diagnostic strategies incorporating mpMRI are now undergoing investigation in prospective trials, for example, the PROMIS study comparing mpMRI against TRUS biopsy [49] and a prospective screening trial utilizing PSA and mpMRI, the 'Göteborg-2' trial, ongoing in Sweden. In a pilot study of 384 men within the Göteborg-1 screening trial, mpMRI with targeted biopsies for men with suspicious lesions and a PSA level in the 'gray zone' improved the detection of significant disease while reducing overdiagnosis (defined as T1c, PSA density <0.15, Gleason Score <7, 2 positive cores, unilateral cancer) compared with systematic biopsy [50] .
The recent 2016 NCCN guideline recommends consideration of 'refined prostate biopsy techniques' (in addition to, or in spite of, biomarkers) for men with negative prostate biopsy, including MRI/ ultrasound fused-guided biopsies, transperineal biopsies,or saturation biopsy [10 & ]. mpMRI in the prediagnostic setting can help find lesions that would otherwise be missed but the negative predictive value is not 100%. Although mpMRI followed by targeted biopsy only to lesions with Prostate Imaging Reporting and Data System scores 3-5 can decrease overdiagnosis and improve the relative sensitivity of any and aggressive prostate cancer compared with TRUS and systematic biopsy, doing so may miss up to 20% of high-grade tumors [51
&&
,52-55,56
]. Next to MRI targeted biopsy for prostate cancer detection, the value of keeping the TRUS-guided systematic biopsies with 11% detection of high-grade prostate cancer (values for individual studies ranging from 7 to 18%) cannot be neglected, when considering the suggestion to omit systematic TRUS-biopsies from the MRI targeted approach [57] .
One recent 2016 study evaluated the value of MRI among men with previous negative biopsy at a tertiary referral center. Upfront risk-based selection using an ERSPC-risk calculator (PSA, DRE, TRUS, and TRUS volume) accurately predicted men with significant mpMRI findings and clinically important disease; use of the risk calculator before imaging would have avoided 51% of mpMRIs and 25% of low-grade prostate cancer diagnosis while missing 10% of high-grade prostate cancers at that time [58] . In sum, although MRI holds great promise in the prediagnostic setting, more large-scale prospective studies are needed and screening with PSA in conjunction with MRI is not ready for ''prime time'' as of 2016.
CONCLUSION AND REFLECTIONS ON COSTS
In summary, there are numerous tests available that can help increase the specificity of PSA, in the initial and repeat biopsy setting. All are at certain, but generally small, cost of decreased sensitivity of detecting high-grade cancer. There is thus a balance between saving biopsies, reducing overdiagnosis and missing, or delaying, detection of high-risk prostate cancer. Moreover, the cost-effectiveness needs also to be taken into consideration as the costs of these tests and strategies are highly variable. As recently argued in a 2016 editorial by Eggener, [59 && ] the 'value of these tests should be determined by clinical value and economic impact rather than marketing campaigns or size of the sales force'.
Thus, the added value of refined approaches to reducing unnecessary testing, biopsy, and overdiagnosis is hampered by the fact that all solutions also carry a risk of missing significant cancer diagnoses. The way forward is a multivariable risk assessment on the basis of readily available clinical data and potentially with the addition of PSA subforms, preferably at low cost. PSA and clinical parameters used in risk calculators perform similarly well as novel, most often more expensive biomarkers, but may be more difficult to implement in clinical practice. MRI in the prediagnostic setting is promising, but not ready for 'prime time'. In men considered to be at high risk of having significant prostate cancer, MRI could be considered.
